Temporal mapping of the anti-tumor effects of nanobody-based MSLN.CAR-T cell therapy in metastatic solid tumors [scRNA-Seq]
Single-cell RNA-seq · mouse · 32 samples
- What it is
- Single-cell RNA-seqGene activity measured in thousands of individual cells, so cell types can be told apart.
- Organism
- Mus musculus (mouse)
- Samples
- 32 samples: 10 conditions, mostly in triplicateGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE303224_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: Single-cell studies usually ship their counts as 10x files (matrix.mtx, barcodes.tsv, features.tsv), an .h5 file, or an .rds / .h5ad object that Seurat or Scanpy can open. Look for those among the supplementary files.
Also filed as BioProject PRJNA1294365 and SRA study SRP602444. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 32 samples.
How we read this: 10 replicated groups read from 32 sample titles; they account for 32 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM9121082 CD45+ cells from the A101 CAR T+ aPDL1 treatment group_biol rep 1 CD45+ cells from the A1…
- GSM9121083 CD45+ cells from the A101 CAR T treatment group_biol rep 1 CD45+ cells from the A1…
- GSM9121084 CD45+ cells from the Mock T treatment group_biol rep 1 CD45+ cells from the Mo…
- GSM9121085 CD45+ cells from the Saline treatment group_biol rep 1 CD45+ cells from the Sa…
- GSM9121086 CD45+ cells from the A101 CAR T+ aPDL1 treatment group_biol rep 2 CD45+ cells from the A1…
- GSM9121087 CD45+ cells from the A101 CAR T treatment group_biol rep 2 CD45+ cells from the A1…
- GSM9121088 CD45+ cells from the Mock T treatment group_biol rep 2 CD45+ cells from the Mo…
- GSM9121089 CD45+ cells from the Saline treatment group_biol rep 2 CD45+ cells from the Sa…
- GSM9121090 CD45+ cells from the A101 CAR T+ aPDL1 treatment group_biol rep 3 CD45+ cells from the A1…
- GSM9121091 CD45+ cells from the A101 CAR T treatment group_biol rep 3 CD45+ cells from the A1…
- GSM9121092 CD45+ cells from the Mock T treatment group_biol rep 3 CD45+ cells from the Mo…
- GSM9121093 CD45+ cells from the Saline treatment group_biol rep 3 CD45+ cells from the Sa…
- GSM9121094 CD45- cells from the A101 CAR T+ aPDL1 treatment group_biol rep 1 CD45- cells from the A1…
- GSM9121095 CD45- cells from the A101 CAR T treatment group_biol rep 1 CD45- cells from the A1…
- GSM9121096 CD45- cells from the Mock T treatment group_biol rep 1 CD45- cells from the Mo…
- GSM9121097 CD45- cells from the Saline treatment group_biol rep 1 CD45- cells from the Sa…
- GSM9121098 CD45- cells from the A101 CAR T+ aPDL1 treatment group_biol rep 2 CD45- cells from the A1…
- GSM9121099 CD45- cells from the A101 CAR T treatment group_biol rep 2 CD45- cells from the A1…
- GSM9121100 CD45- cells from the Mock T treatment group_biol rep 2 CD45- cells from the Mo…
- GSM9121101 CD45- cells from the Saline treatment group_biol rep 2 CD45- cells from the Sa…
- GSM9121102 CD45- cells from the A101 CAR T+ aPDL1 treatment group_biol rep 3 CD45- cells from the A1…
- GSM9121103 CD45- cells from the A101 CAR T treatment group_biol rep 3 CD45- cells from the A1…
- GSM9121104 CD45- cells from the Mock T treatment group_biol rep 3 CD45- cells from the Mo…
- GSM9121105 CD45- cells from the Saline treatment group_biol rep 3 CD45- cells from the Sa…
- GSM9121106 CD45- cells from the Saline_aPDL1 treatment group_biol rep 1 CD45- cells from the Sa…
- GSM9121107 CD45- cells from the Saline_aPDL1 treatment group_biol rep 2 CD45- cells from the Sa…
- GSM9121108 CD45- cells from the Saline_aPDL1 treatment group_biol rep 3 CD45- cells from the Sa…
- GSM9121109 CD45- cells from the A101 CAR T+ aPDL1 treatment group_biol rep 4 CD45- cells from the A1…
- GSM9121110 CD45+ cells from the Saline_aPDL1 treatment group_biol rep 1 CD45+ cells from the Sa…
- GSM9121111 CD45+ cells from the Saline_aPDL1 treatment group_biol rep 2 CD45+ cells from the Sa…
- GSM9121112 CD45+ cells from the Saline_aPDL1 treatment group_biol rep 3 CD45+ cells from the Sa…
- GSM9121113 CD45+ cells from the A101 CAR T+ aPDL1 treatment group_biol rep 4 CD45+ cells from the A1…
- GSE234977 Pan-cancer mapping of single CD8+ T cell profiles reveals a TCF1:CXCR6 axis regulating CD28 co-stimulation and anti-tumor immunity 32 samples shares anti-tumor, mapping
- GSE234974 Pan-cancer mapping of single CD8+ T cell profiles reveals a TCF1:CXCR6 axis regulating CD28 co-stimulation and anti-tumor immunity I 24 samples shares anti-tumor, mapping
- GSE245838 Anchored screening identifies transcription factor blueprints underlying dendritic cell diversity and subset-specific anti-tumor immunity [mouse scRNA-seq] 21 samples shares anti-tumor, scrna-seq
- GSE313761 Single-cell screens identify ADAM12 as a fibroblast checkpoint impeding anti-tumor immunity - scRNA-seq of Adam12CKO Mouse Model CD45- cells 11 samples shares anti-tumor, scrna-seq
- GSE298720 Global gene expression profiles were compared among IL1B-treated, Ad-OSCAR-treated, and control mice, with or without subsequent treatment with OSCAR inhibitors (Brivudine or Adefovir). 35 samples shares car-t
- GSE266166 B-ALL GPR65 expression influences susceptibility to CAR-T therapy through a VEGF and macrophage-dependent mechanism 22 samples shares car-t
- GSE293295 Discovery of BMS-986408, a First-In-Class Dual DGK⍺ and DGK Inhibitor That Unleashes PD-1 Checkpoint and CAR-T Cell Immunotherapies 20 samples shares car-t
- GSE310249 Modulating AP-1 enables CAR-T cells to establish an intratumoral stem-like reservoir and overcomes resistance to PD-1 blockade 18 samples shares car-t
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.